Akebia Therapeutics (AKBA) Net Income towards Common Stockholders (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$9.1 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 248.13% year-over-year to -$9.1 million in Q1 2026; TTM through Mar 2026 was -$20.5 million, a 54.73% increase from a year earlier, with the FY2025 full-year figure at -$5.3 million, up 92.3% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$9.1 million, up from -$12.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for AKBA reached as high as $29.4 million in Q2 2022 and fell as low as -$63.5 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$13.4 million across 5 years, with a median of -$11.2 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders jumped 135.46% in 2022 and sank 3814.01% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$4.1 million in 2022, then surged by 114.89% to $614000.0 in 2023, then sank by 3814.01% to -$22.8 million in 2024, then soared by 46.31% to -$12.2 million in 2025, then rose by 26.05% to -$9.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$9.1 million in Q1 2026, -$12.2 million in Q4 2025, and $540000.0 in Q3 2025.